Table of Contents page: Clinical Lung Cancer

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Select all

Download started.
Ok

Please select at least one article in order to proceed.

Current and Emerging Treatment Options for Patients With Relapsed Small-cell Lung Carcinoma: A Systematic Literature Review

Reyes Bernabé-Caro,
Yuanbin Chen,
Afshin Dowlati,
Paula Eason

Published online: February 07, 2023

p185-208

Open Access

Liquid Biopsy Screening for Early Detection of Lung Cancer: Current State and Future Directions

William Zhu,
Kyra Love,
Stacy W. Gray,
Dan J. Raz

Published online: January 26, 2023

p209-217

Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study

Melissa L. Johnson,
James Strauss,
Manish R. Patel,
...
Josée Morin,
Richard Chao,
Balazs Halmos

Published online: February 07, 2023

p218-227

A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer

Wade T. Iams,
Meridith L. Balbach,
Sharon Phillips,
...
Jorge Nieva,
Tejas Patil,
D. Ross Camidge

Published online: February 07, 2023

p228-234

Open Access

Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non–small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90%

Mohsin Shah,
Ronac Mamtani,
Melina E. Marmarelis,
Sean Hennessy

Published online: February 28, 2023

p235-243

Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma

Colton Ladbury,
Tariq Abuali,
Jason Liu,
...
Terence Williams,
Scott Glaser,
Arya Amini

Published online: January 20, 2023

p244-251

Tumor Volume Is a Better Prognostic Factor than Greatest Tumor Diameter in Operated Stage I-III Non–Small-Cell Lung Cancer

Ayşe Ocak Duran,
Mevlude Inanc,
Oktay Bozkurt,
Ersin Ozaslan,
Metin Ozkan

Published online: March 04, 2023

p252-259

Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data

Howard West,
Xiaohan Hu,
Su Zhang,
...
Anya Jiang,
James Signorovitch,
Ayman Samkari

Published online: December 24, 2022

p260-268

Open Access

Upfront and Repeated Stereotactic Radiosurgery in Patients With Brain Metastases From NSCLC

Anna S. Krämer,
Sebastian Adeberg,
Dorothea Kronsteiner,
...
Stefan Rieken,
Jürgen Debus,
Rami A. El Shafie

Published online: January 20, 2023

p269-277

Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non–small-Cell Lung Cancer Patients

Minjiang Chen,
Yan Xu,
Jing Zhao,
...
Li Zhang,
Wei Zhong,
Mengzhao Wang

Published online: December 27, 2022

p278-286

Open Access

The Association of Improved Overall Survival with NSAIDs in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

Nikhil T. Sebastian,
William A. Stokes,
Madhusmita Behera,
...
Suresh S. Ramalingam,
Vikas P. Sukhatme,
Drew Moghanaki

Published online: January 20, 2023

p287-294

Open Access

Anaplastic Lymphoma Kinase (ALK) Positive Neuroendocrine Tumor of Lung With Favorable Response to Alectinib (ALK Inhibitor)

Bipin Ghimire,
Ashbita Pokharel,
Ujjwal Karki,
Shrinjaya Thapa,
Mohammad Muhsin Chisti

Published online: December 25, 2022

e113-e116

Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression

Misha C. Tran,
Garth W. Strohbehn,
Theodore G. Karrison,
...
Marina C. Garassino,
Everett E. Vokes,
Christine M. Bestvina

Published online: January 25, 2023

e117-e121

Open Access

Rationale and Design of a Single-Arm, Phase 2, Multi-Center Study of Chemo-Immunotherapy Followed by Hypo-Fractionated RT and Maintenance Immunotherapy in Patients With Unresectable Stage III NSCLC: The DEDALUS Trial

Andrea Riccardo Filippi,
Francesco Agustoni,
Stefano Arcangeli,
...
Paolo Pedrazzoli,
Umberto Malapelle,
Francesco Grossi

Published online: January 20, 2023

e122-e125

Vascular Invasion Predicts Recurrence in Stage IA2-IB Lung Adenocarcinoma but not Squamous Cell Carcinoma

Lubna Suaiti,
Travis B. Sullivan,
Kimberly M. Rieger-Christ,
Elliot L. Servais,
Kei Suzuki,
Eric J. Burks

Published online: December 25, 2022

e126-e133

Prevalence and Predictability of Occult Satellite Nodules in Clinical Stage Ia Non-small Cell Lung Cancer following Lobectomy

Peter J. Kneuertz,
Mahmoud Abdel-Rasoul,
Desmond M. D'Souza,
Susan D. Moffatt-Bruce,
Robert E. Merritt

Published online: December 27, 2022

e134-e140

Adequate Number of Lymph Nodes Sampled May Determine Appropriate Surgical Modality for Early-Stage NSCLC: A Population-Based Real-World Study

Lixian Ling,
Hongjuan Zheng,
Haiping Lin,
...
Yang Lou,
Ting Jiang,
Jianfei Fu

Published online: December 25, 2022

e141-e151

Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade

Vishal Navani,
Daniel E. Meyers,
Yibing Ruan,
...
Randeep Sangha,
Winson Y. Cheung,
Aliyah Pabani

Published online: January 20, 2023

e152-e159

Open Access

Editorial Board

Published in issue: May 2023

A3-A6

Latest

Popular Articles

Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial

Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications

Brief Report: Predictive value of PD-L1 Expression in non–Small-Cell Lung Cancer - Should we Set the Bar Higher for Monotherapy?

Latest Articles

Alternating therapy with osimertinib and afatinib blockades EGFR secondary mutation in EGFR-mutant lung cancer: A single-arm phase 2 trial

Lung cancer in patients with Lynch Syndrome: Association or Coincidence?

Chemoimmunotherapy as The First-Line Treatment for Patients with Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status of 2 or 3

For Authors

Journal Information

Companion Journals

Access

Contact

Follow Us

May 2023

Reviews

Current and Emerging Treatment Options for Patients With Relapsed Small-cell Lung Carcinoma: A Systematic Literature Review

Liquid Biopsy Screening for Early Detection of Lung Cancer: Current State and Future Directions

Original Studies

Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study

A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer

Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non–small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90%

Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma

Tumor Volume Is a Better Prognostic Factor than Greatest Tumor Diameter in Operated Stage I-III Non–Small-Cell Lung Cancer

Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data

Upfront and Repeated Stereotactic Radiosurgery in Patients With Brain Metastases From NSCLC

Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non–small-Cell Lung Cancer Patients

The Association of Improved Overall Survival with NSAIDs in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

Available Exclusively Online at www.clinical-lung-cancer.com

Anaplastic Lymphoma Kinase (ALK) Positive Neuroendocrine Tumor of Lung With Favorable Response to Alectinib (ALK Inhibitor)

Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression

Rationale and Design of a Single-Arm, Phase 2, Multi-Center Study of Chemo-Immunotherapy Followed by Hypo-Fractionated RT and Maintenance Immunotherapy in Patients With Unresectable Stage III NSCLC: The DEDALUS Trial

Vascular Invasion Predicts Recurrence in Stage IA2-IB Lung Adenocarcinoma but not Squamous Cell Carcinoma

Prevalence and Predictability of Occult Satellite Nodules in Clinical Stage Ia Non-small Cell Lung Cancer following Lobectomy

Adequate Number of Lymph Nodes Sampled May Determine Appropriate Surgical Modality for Early-Stage NSCLC: A Population-Based Real-World Study

Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade

Frontmatter

Editorial Board

Table of Contents